Dengue vaccine is only
recommended in those who have previously had dengue fever. It is given as three
injections over a year.
Statistics:
The global Dengue
Vaccine Market is estimated to account for US$ 1,262.0 Mn in terms of value
by the end of 2027.
Global Dengue Vaccine Market:
Drivers
Increasing demand for dengue
vaccine is expected to propel growth of the global dengue vaccine market. For
instance, the researchers at International Vaccine Institute, South Korea,
projected that around 7.8–62.9 million doses of dengue vaccine are required for
only routine vaccination of 12–23 mo cohort in first 5 years of the period
2015–2022 with different vaccination schedules.
Global Dengue Vaccine Market:
Opportunities
R&D of vaccines that are
effective against all age groups is expected to offer lucrative growth
opportunities for players in the global dengue vaccine market. For instance, in
November 2019, Takeda Pharmaceutical Company Limited announced that TAK-003,
its dengue vaccine candidate demonstrated protection in children ages four to
16 years, regardless of previous dengue exposure.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/23
Global Dengue Vaccine Market:
Restraints
Dengue vaccines such as Dengvaxia
poses high risk to people without prior dengue infection. This is expected to
hinder adoption of dengue vaccines, thereby hindering growth of the market.
Key Takeaways:
The Government Institutes segment
in the global dengue vaccines market was valued at US$ 169.6 Mn in 2019 and is
expected to reach US$ 657.6 by 2027 at a CAGR of 18.5% during the forecast
period. The growth of the segment
is attributed increase in government initiatives to promote awareness and
provide vaccination facility to cope up with increasing incidence of dengue in
respective countries.
Market Trends
Major players in the market are
focused on developing recombinant subunit vaccines that are effective against
dengue. For instance, Merck is assessing the immunogenicity and safety of an
investigational tetravalent recombinant subunit vaccine for dengue. The study
completed phase I stage as of 2019.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/dengue-vaccines-market-23
Major players in the market are
focused on adopting M&A strategies to expand their product portfolio. For
instance, in January 2019, Takeda Pharmaceutical Company Limited completed
acquisition of Shire plc.
Global Dengue Vaccine Market:
Competitive Landscape
Major players operating in the
global dengue vaccine market include, Sanofi, Takeda Pharmaceutical Company
Limited, GlaxoSmithKline, and Merck & Co.
Global Dengue Vaccine Market: Key
Developments
January 2020: Codagenix, a
company developing vaccines and viral therapies for illnesses ranging from the
flu and respiratory viruses to dengue fever, raised US$ 20 million in a new
round of financing
November 2019: Takeda
Pharmaceutical Company Limited started a plant to produce dengue vaccine in
Germany
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/23
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
